Fielding questions from the audience, expert oncologists discuss clinical trials, molecular testing, and early-stage disease in the context of HER2-amplified colorectal cancer.
EMA Validates MAA for Frontline Nivolumab/Ipilimumab for MSI-H/dMMR mCRC
Lunning and Rutherford Detail Considerations for BV-AVD Use in Older Patients With Hodgkin Lymphoma
Next-Generation ColoAlert Screening Test Shows High Sensitivity, Specificity for CRC and Adenoma Detection
Kitko and Patel Emphasize the Importance of GVHD Research and Awareness
HER2 Expression May Hold the Key to Predicting Survival Outcomes in CRC
Data Continue to Illustrate Potential Role of Partial Breast Irradiation in Early-Stage Breast Cancer
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist
Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer
Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC